E-Cigarettes vs. Nicotine Therapy to Stop Smoking

E-cigarettes were more effective for smoking cessation than nicotine-replacement therapy according to this randomized study recently published in the New England Journal of Medicine (NEJM). Both must be accompanied by medical and psychological support for optimal results.

Enfermedad pulmonar y cigarrillos electrónicos: Nuevos dispositivos con nuevas enfermedadesWhile e-cigarettes are commonly used as a smoking cessation strategy, evidence is limited regarding their effectiveness as compared with other strategies such as approved nicotine products (chewing gum, candy, patches, etc.) that act as nicotine replacement to help patients stop smoking permanently.

 

A total of 886 participants attending dedicated U.K. stop-smoking services underwent randomization to either nicotine-replacement products (different combinations or presentations) for 3 months or an e-cigarette (a second-generation refillable e-cigarette with one bottle of nicotine e-liquid [18 mg/mL]). Flavor and strength were left to the patients’ choice. Treatment was to be followed for at least 4 weeks.


Read also: E-Cigarettes: No Definitive Evidence on Their Potential Cardiovascular Effect, but Some Suggest Caution.


For both treatment arms, treatment included counseling follow-up for at least 4 weeks.

 

The primary outcome was sustained abstinence for one year, which was validated biochemically at the final follow-up visit. Participants who were lost to follow-up or did not access biochemical validation were considered to not be abstinent.

 

The abstinence rate at one year was 18% in the e-cigarette group vs. 9.9% in the nicotine-replacement group (relative risk [RR]: 1.83; 95% confidence interval [CI]: 1.30 to 2.58; p < 0.001). While the abstinence rate for e-cigarettes almost doubled the rate for nicotine-replacement therapy, 18% is still very low and we should insist so that more patients can quit smoking for good.


Read also: Several Features Define a Hostile Neck in AAA patients, but Only One Makes the Difference.


The most frequently reported events were throat or mouth irritation for the e-cigarette group and nausea for the nicotine-replacement group.

 

Symptoms such as cough and phlegm production were also minor in the e-cigarette group.

 

There were no differences between groups in the incidence of bronchospasm or dyspnea.

 

Conclusion

E-cigarettes were more effective for smoking cessation than nicotine-replacement therapy when both were accompanied by psychological and medical advice.

 

Original title: A Randomized Trial of E-Cigarettes Versus Nicotine-Replacement Therapy.

Reference: Peter Hajek et al. N Engl J Med. 2019 Feb 14;380(7):629-637.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Ticagrelor vs Clopidogrel in ACS Patients Receiving DOAC After PCI: More Bleeding Without Ischemic Benefit?

In patients with acute coronary syndrome (ACS) who require direct oral anticoagulation (DOAC) and undergo percutaneous coronary intervention (PCI), current guidelines recommend a dual...

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Coronary Obstruction During TAVI: A New Volumetric Index to Consider

Coronary obstruction during TAVI is an uncommon but potentially catastrophic complication, particularly in valve-in-valve procedures, in anatomies with small sinuses of Valsalva, low coronary...

EARLY TAVR: Impact of Age on Outcomes of Early TAVR in Asymptomatic Patients

Asymptomatic severe aortic stenosis represents an increasingly common clinical challenge. Although current guidelines recommend intervention once symptoms develop or left ventricular dysfunction occurs, concerns...

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...